SCHEMBL16719423

SCHEMBL16719423

Cc1nc2cc(-c3c(C#Cc4c[nH]c5ncccc45)cccc3C(=O)O)ccc2s1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CAMKK2 Q96RR4 2/20 0.38
▸ SYK P43405 1/20 0.38
▸ CAMKK1 Q8N5S9 1/20 0.37
▸ NPC1 O15118 2/20 0.37
▸ RAB9A P51151 2/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ IL1B P01584 1/20 0.37
▸ DHODH Q02127 1/20 0.36
▸ PKM P14618 1/20 0.36
▸ LRRK2 Q5S007 1/20 0.35
▸ MAP2K1 Q02750 1/20 0.35
▸ RXFP1 Q9HBX9 1/20 0.35
▸ EIF2AK3 Q9NZJ5 1/20 0.34
▸ GRM1 Q13255 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ HDAC4 P56524 1/20 0.34
▸ INSR P06213 1/20 0.34
▸ ALK Q9UM73 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16731663 0.81 NPC1 (0.40) SYKNPC1RAB9ASMN1; SMN2PKM
SCHEMBL18227597 0.80 NPC1 (0.45) NPC1RAB9ASMN1; SMN2DHODHEIF2AK3
SCHEMBL29377604 0.79 DHODH (0.50) DHODHPKMLRRK2MAP2K1HTT
SCHEMBL16720578 0.79 DHODH (0.50) DHODHPKMLRRK2MAP2K1HTT
SCHEMBL16719775 0.78 SYK (0.42) CAMKK2SYKCAMKK1LRRK2MAP2K1
SCHEMBL16720324 0.77 NPC1 (0.40) SYKNPC1RAB9ASMN1; SMN2EIF2AK3
SCHEMBL16719567 0.74 LRRK2 (0.48) CAMKK2CAMKK1DHODHLRRK2MAP2K1
SCHEMBL18227598 0.74 NPC1 (0.45) NPC1RAB9ASMN1; SMN2DHODHEIF2AK3
SCHEMBL16720472 0.72 LRRK2 (0.48) CAMKK2CAMKK1LRRK2MAP2K1KDM4E
SCHEMBL16719516 0.72 MYC (0.47) CAMKK2CAMKK1DHODHLRRK2MAP2K1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220396551-A1 EBNA1 Inhibitors and Their Method of Use WISTAR INST (US) 2022-12-15 — — US claimed
EP-3068758-B1 EBNA1 INHIBITORS AND THEIR METHOD OF USE WISTAR INST (US) 2021-09-08 — — EP claimed
US-20180086699-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2018-03-29 — — US claimed
US-20160289185-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-10-06 — — US claimed
EP-3068758-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE The Wistar Institute Of Anatomy And Biology (US) 2016-09-21 — — EP claimed
WO-2015073864-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE THE WISAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2015-05-21 — — WO claimed
US-12258314-B2 EBNA1 inhibitors and their method of use THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2025-03-25 — — US disclosed
US-20220396551-A1 EBNA1 Inhibitors and Their Method of Use WISTAR INST (US) 2022-12-15 — — US disclosed
US-20220396551-A1 EBNA1 Inhibitors and Their Method of Use WISTAR INST (US) 2022-12-15 — — US disclosed
US-11242317-B2 EBNA1 inhibitors and their method of use THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2022-02-08 — — US disclosed
US-11242317-B2 EBNA1 inhibitors and their method of use THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2022-02-08 — — US disclosed
EP-3068758-B1 EBNA1 INHIBITORS AND THEIR METHOD OF USE WISTAR INST (US) 2021-09-08 — — EP disclosed
EP-3068758-B1 EBNA1 INHIBITORS AND THEIR METHOD OF USE WISTAR INST (US) 2021-09-08 — — EP disclosed
US-9856214-B2 EBNA1 inhibitors and their method of use THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2018-01-02 — — US disclosed
US-20160289185-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-10-06 — — US disclosed
US-20160289185-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-10-06 — — US disclosed
US-20160289185-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-10-06 — — US disclosed
EP-3068758-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE The Wistar Institute Of Anatomy And Biology (US) 2016-09-21 — — EP disclosed
WO-2015073864-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE THE WISAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2015-05-21 — — WO disclosed
WO-2015073864-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE THE WISAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2015-05-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12258314-B2 EBNA1 inhibitors and their method of use EBNA1BP2, MLLT1, PML CAMKK2 3451/4885SYK 1194/4885CAMKK1 2288/4885
US-11242317-B2 EBNA1 inhibitors and their method of use EBNA1BP2, MLLT1, PML CAMKK2 3451/4885SYK 1194/4885CAMKK1 2288/4885
US-20160289185-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE MCM5, EBNA1BP2, MLLT1 CAMKK2 3867/4885SYK 1324/4885CAMKK1 2892/4885
US-20180086699-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE EBNA1BP2, MLLT1, PML CAMKK2 3451/4885SYK 1194/4885CAMKK1 2288/4885
US-20220396551-A1 EBNA1 Inhibitors and Their Method of Use EBNA1BP2, MLLT1, PML CAMKK2 3451/4885SYK 1194/4885CAMKK1 2288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback